Quad Cities Investment Group LLC Has $311,000 Position in Novartis AG (NYSE:NVS)

Quad Cities Investment Group LLC cut its holdings in shares of Novartis AG (NYSE:NVS) by 14.0% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,705 shares of the company’s stock after selling 441 shares during the period. Quad Cities Investment Group LLC’s holdings in Novartis were worth $311,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Dimensional Fund Advisors LP grew its stake in shares of Novartis by 23.1% in the second quarter. Dimensional Fund Advisors LP now owns 7,407,692 shares of the company’s stock worth $788,626,000 after purchasing an additional 1,389,610 shares during the last quarter. Janus Henderson Group PLC increased its stake in shares of Novartis by 0.6% in the first quarter. Janus Henderson Group PLC now owns 2,568,728 shares of the company’s stock valued at $248,473,000 after buying an additional 16,015 shares during the period. Principal Financial Group Inc. raised its position in shares of Novartis by 0.6% during the first quarter. Principal Financial Group Inc. now owns 2,523,334 shares of the company’s stock worth $244,082,000 after acquiring an additional 14,686 shares during the last quarter. Mondrian Investment Partners LTD lifted its stake in shares of Novartis by 40.1% in the first quarter. Mondrian Investment Partners LTD now owns 2,065,739 shares of the company’s stock worth $199,819,000 after acquiring an additional 590,830 shares during the period. Finally, Magnetar Financial LLC boosted its holdings in Novartis by 53.7% in the first quarter. Magnetar Financial LLC now owns 1,906,046 shares of the company’s stock valued at $184,372,000 after acquiring an additional 666,104 shares during the last quarter. 13.12% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages have weighed in on NVS. Barclays upgraded Novartis to a “strong sell” rating in a report on Monday, June 24th. Jefferies Financial Group cut Novartis from a “buy” rating to a “hold” rating in a research report on Tuesday, September 3rd. Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of Novartis in a research report on Friday, July 19th. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $121.00 target price (up from $119.00) on shares of Novartis in a research report on Thursday, September 5th. Finally, Bank of America downgraded shares of Novartis from a “buy” rating to a “neutral” rating and dropped their price objective for the company from $135.00 to $130.00 in a report on Wednesday, September 11th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $120.70.

Novartis Trading Down 0.0 %

NYSE NVS traded down $0.02 during trading on Thursday, hitting $116.55. 356,021 shares of the company’s stock traded hands, compared to its average volume of 1,344,965. Novartis AG has a 12-month low of $92.19 and a 12-month high of $120.92. The company has a debt-to-equity ratio of 0.47, a current ratio of 0.93 and a quick ratio of 0.72. The stock has a fifty day moving average of $116.09 and a two-hundred day moving average of $107.69. The firm has a market cap of $238.23 billion, a P/E ratio of 15.73, a PEG ratio of 1.71 and a beta of 0.57.

Novartis (NYSE:NVS) last released its quarterly earnings results on Thursday, July 18th. The company reported $1.97 EPS for the quarter, beating analysts’ consensus estimates of $1.87 by $0.10. The business had revenue of $12.87 billion during the quarter, compared to analyst estimates of $12.24 billion. Novartis had a return on equity of 34.56% and a net margin of 33.76%. During the same quarter in the prior year, the company posted $1.83 EPS. As a group, sell-side analysts expect that Novartis AG will post 7.52 EPS for the current year.

Novartis Company Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.